

UBE2Q1 (NICE-5) [6His-tagged]

E2 – Ubiquitin Conjugating Enzyme

Alternate Names: UBE2Q1, NICE5, PRO3094, GTAP

Cat. No. **62-0081-020**
Lot. No. **1832**

Quantity: 20 µg
Storage: -70°C

FOR RESEARCH USE ONLY

NOT FOR USE IN HUMANS



CERTIFICATE OF ANALYSIS Page 1 of 1

Background

The enzymes of the ubiquitylation pathway play a pivotal role in a number of cellular processes including regulated and targeted proteasomal degradation of substrate proteins. Three classes of enzymes are involved in the process of ubiquitylation; activating enzymes (E1s), conjugating enzymes (E2s) and protein ligases (E3s). UBE2Q1 is a member of the E2 conjugating enzyme family and cloning of the human gene was described by Marenholz *et al.* (2001). UBE2Q1 shares 50-75% sequence identity with its homologues in *Mus musculus*, *Drosophila*, *C. elegans* and *Xenopus*. Murine UBE2Q1 has a conserved sequence for ubiquitin binding shared by all the ubiquitin-conjugating enzymes, however its NH(2)-terminal domain appears critical for the binding and internalization of cell surface galactosyltransferase 1 (GalT1) in embryonic stem cells. UBE2Q1 regulates GalT1-associated, laminin-dependent embryonic cell adhesion and the formation of embryoid bodies (Wassler *et al.*, 2008).

References:

Marenholz I, Zirra M, Fischer DF, Backendorf C, Ziegler A, Mischke D (2001) Identification of human epidermal differentiation complex (EDC)-encoded genes by subtractive hybridization of entire YACs to a gridded keratinocyte cDNA library. *Genome Res* 11, 341-55.

Wassler MJ, Shur BD, Zhou W, Geng YJ (2008) Characterization of a novel ubiquitin-conjugating enzyme that regulates beta1,4-galactosyltransferase-1 in embryonic stem cells. *Stem Cells* 26, 2006-18.

Physical Characteristics

Species: human

Source: *E. coli* expression

Quantity: 20 µg

Concentration: 1 mg/ml

Formulation: 50 mM HEPES pH 7.5, 150 mM sodium chloride, 2 mM dithiothreitol, 10% glycerol

Molecular Weight: ~50 kDa

Purity: >98% by InstantBlue™ SDS-PAGE

Stability/Storage: 12 months at -70°C; aliquot as required


Protein Sequence:

MHHHHHSSGLVPRGRSHMASMTGGQQMGRG
SEF**QQPQPQGGQQ**PGPGQQLGQGGAAPGAG
GGPGGGPGPGPCLRRELKLLSEIFHRGHER
FRIASACLDELSCFLLAGAGGAGGAAPGPHLP
PRGSVPGDPVRIHCNITESYPVPPPIWSVESD
DPNLAAVLERLVDIKKNGTLLLQHLKRIISDL
CKLYNLPQHPDVEMLDQPLPAEQCTQEDVSSD
EDEEMPEDTEDLDHYEMKEEPAEGKKSDD
GIGKENLAILEKIKKNQRQDYLNNAVSGSVQAT
DRLMKELRDIYRSQSFKGGNYAVELVNDLSLYD
WNVKLLKVDQDSALHNDLQILKEKEGADFILL
NFSFKDNFPDPPFVRVSPVLSGGYVLGG
GAICMELLTKQGWSSAYSIESVMQISATLVKG
KARVQFGANKSQYSLTRAQQSYKSLVQIHEKNGW
YTPPKEDG

Tag (**bold text**): N-terminal His
Protease cleavage site: Thrombin (**LVPR**▼**GS**)
UBE2Q1 (regular text): Start **bold italics** (amino acid residues 2-422). Accession number: NP_060052

Quality Assurance

Purity: 4-12% gradient SDS-PAGE InstantBlue™ staining
Lane 1: MW markers
Lane 2: 1 µg His-UBE2Q1



Protein Identification:

Confirmed by mass spectrometry.

E2-Ubiquitin Thioester Loading Assay:

The activity of His-UBE2Q1 was validated by loading E1 UBE1 activated ubiquitin onto the active cysteine of the His-UBE2Q1 E2 enzyme via a transthioesteration reaction. Incubation of the UBE1 and His-UBE2Q1 enzymes in the presence of ubiquitin and ATP at 30°C was compared at two time points, T₀ and T₁₀ minutes. The sensitivity of this ubiquitin/His-UBE2Q1 thioester bond to the reducing agent DTT was confirmed.



www.ubiquigent.com
Dundee, Scotland, UK

ORDERS / SALES SUPPORT

International: +1-617-245-0003
US Toll-Free: 1-888-4E1E2E3 (1-888-431-3233)
Email: sales.support@ubiquigent.com

UK HQ and TECHNICAL SUPPORT

International: +44 (0) 1382 381147 (9AM-5PM UTC)
US/Canada: +1-617-245-0020 (9AM-5PM UTC)
Email: tech.support@ubiquigent.com

Email services@ubiquigent.com for enquiries regarding compound profiling and/or custom assay development services.

© Ubiquigent 2011. Unless otherwise noted, Ubiquigent, Ubiquigent logo and all other trademarks are the property of Ubiquigent, Ltd.

Limited Terms of Use: For research use only. Not for use in humans or for diagnostics. Not for distribution or resale in any form, modification or derivative OR for use in providing services to a third party (e.g. screening or profiling) without the written permission of Ubiquigent, Ltd.

Lot-specific COA version tracker: v1.0.0